Mizral 20mg Tablet SR is a slow-release formulation of propranolol, a non-selective beta-blocker, indicated for the management of hypertension, angina pectoris, and prevention of migraine. This once-daily tablet is designed to provide a sustained release of the active ingredient over a 24-hour period, allowing for consistent therapeutic effects. Propranolol, the active salt, works by inhibiting the sympathetic nervous system, thereby reducing cardiac output, blood pressure, and peripheral resistance. The therapeutic effects of Mizral 20mg Tablet SR include a decrease in blood pressure, heart rate, and myocardial oxygen demand, as well as a reduction in the frequency and severity of migraine attacks. Additionally, this medication has been shown to be effective in preventing cardiac arrhythmias, supraventricular tachycardia, and hypertrophic cardiomyopathy. Mizral 20mg Tablet SR is contraindicated in patients with severe bronchial asthma, second- or third-degree atrioventricular block, and patients with a history of congestive heart failure. As with any medication, patients should be monitored for potential side effects, which may include fatigue, dizziness, and cold extremities.